Maxcyte (MXCT) Gains from Investment Securities (2020 - 2021)

Maxcyte (MXCT) posted quarterly Gains from Investment Securities of $287200.0 for Q3 2021, up 2688.35% quarter-over-quarter from $10300.0 in Q2 2021.

Maxcyte (MXCT) Gains from Investment Securities (2020 - 2021) Analysis & Trends

Maxcyte (MXCT) has reported Gains from Investment Securities for 2 consecutive years, with $287200.0 the latest figure, recorded in Q3 2021.

In Q3 2021, Gains from Investment Securities changed N/A year-over-year to $287200.0; the TTM figure through Dec 2021 stood at $645400.0 (changed N/A YoY), while the FY2021 annual figure was $645400.0, up 76.1% from the prior year.
Gains from Investment Securities rose to $287200.0 in Q3 2021 per MXCT's latest filing, from $10300.0 in the prior quarter.
Across five years, Gains from Investment Securities topped out at $347900.0 in Q1 2021 and bottomed at $10300.0 in Q2 2021.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Abbott Laboratories	199.45 Bn	193.85 Bn	7.27 Bn
2	Stryker	127.62 Bn	124.14 Bn	4.50 Bn
3	Medtronic	118.98 Bn	109.76 Bn	6.41 Bn
4	Boston Scientific	73.41 Bn	72.87 Bn	3.85 Bn
5	Edwards Lifesciences	51.89 Bn	47.64 Bn	1.35 Bn
6	Dexcom	34.33 Bn	32.38 Bn	830.00 Mn
7	GE HealthCare Technologies	33.87 Bn	31.76 Bn	2.18 Bn
8	Koninklijke Philips	26.37 Bn	23.05 Bn	4.55 Bn
9	Steris	23.04 Bn	22.56 Bn	684.20 Mn
10	Maxcyte	147.95 Mn	147.95 Mn	5.60 Mn

Download Data